NIPPON KAYAKU and Eli Lilly Enter into Licensing Agreement of Necitumumab, a humanized anti EGFR Monoclonal Antibody, in JAPAN
2019/04/22Tokyo, Japan, April 22, 2019 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) and Eli Lilly and Company (Head Office: Indiana US ; Chairman and CEO: David A.Ricks ;hereinafter referred to as “Lilly”) today announced licensing agreement for the manufacturing and commercialization of Necitumumab in Japan．
Necitumumab is a recombinant human IgG1 monoclonal antibody that is designed to block the ligand binding site of human epidermal growth factor receptor 1 (EGFR). In Japan, Eli Lilly Japan (Head Office: Hyogo; Representative Director and President: Patrik Jonsson) has submitted an application for manufacturing and marketing approval to the Ministry of Health, Labour and Welfare.
Nippon Kayaku currently sells 32 types of anti-cancer drugs, and is building a business foundation focusing on oncology. With a goal of early launch of this product, we expect to make a significant contribution to cancer patients, their families and medical professionals.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels
[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.